Extended Data Figure 9 : LATS ablation reduces the efficacy of fulvestrant treatment.

From: The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα

Extended Data Figure 9

a, LATS is downregulated in the majority of human breast cancer samples and cell lines. Immunoblots of PHBECs and primary human breast cancer samples (top), MCF10A cells and basal (bottom left) and luminal (bottom right) breast cancer cell lines. b, shLATS reduces sensitivity to fulvestrant by preventing ERα degradation. Colony areas of T47D (top) and of MCF7 (bottom) shNT- and shLATS-treated cell lines in response to fulvestrant and tamoxifen treatment. (n = 9 experimental replicates). c, shLATS-treated tumours are partially resistant to fulvestrant. Tumour growth curves of shNT- and shLATS-treated T47D cell-bearing animals treated with 2.5 mg fulvestrant per 25 g, as indicated n = 5 biological replicates. d, Low LATS expression is associated with poor outcome in patients treated with anti-oestrogens but not in the tamoxifen-only treated subgroup. Kaplan–Meier analysis of relapse-free survival of n = 643 (left), n = 346 (middle), n = 489 (right) patients with breast cancer. Data are mean ± s.d. (b, c); *P < 0.05.